Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Holding CAPR?
Track your performance easily
CAPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.68 - $23.40
Previous Close$21.46
Volume466.25K
Average Volume (3M)2.95M
Market Cap
$1.01B
Enterprise Value$965.94M
Total Cash (Recent Filing)$29.46M
Total Debt (Recent Filing)$5.21M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 07, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding32,538,930
10 Day Avg. Volume2,402,124
30 Day Avg. Volume2,948,071
Standard Deviation0.74
R-Squared0.08
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)61.31
Price to Sales (P/S)26.10
Price to Cash Flow (P/CF)-14.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue35.57
Enterprise Value/Gross Profit38.36
Enterprise Value/Ebitda-36.31
Forecast
1Y Price Target
$40.67Price Target Upside85.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Capricor Therapeutics News
Ownership Overview
16.73% Insiders
4.85% Mutual Funds
<0.01% Other Institutional Investors
72.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $2.68 and its highest was $23.40 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 9 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 07, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.356 by $0.006.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -$0.36.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 45,463,017 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.356. Following the earnings report the stock price went up 8.989%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Among the largest hedge funds holding Capricor Therapeutics’s share is Woodline Partners LP. It holds Capricor Therapeutics’s shares valued at N/A.
---
Capricor Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (85.79% Upside)
$40.67 (85.79% Upside)
Blogger Sentiment
Neutral
CAPR Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 68.9%
Last 30 Days ▲ 68.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
688.97%
12-Months-Change
Fundamentals
Return on Equity
-392.69%
Trailing 12-Months
Asset Growth
-16.81%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
---
CAPR Earnings Call
Q2 2024
0:00 / 0:00
---
CAPR Stock 12 Month Forecast
Average Price Target
$40.67
▲(85.79% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Brainstorm Cell Therapeutics
―
Plus Therapeutics
―
X4 Pharmaceuticals
―
Best Analysts Covering CAPR
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+338.82%
reiterated a buy rating 19 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +338.82% per trade.
---